SBIR/STTR Research Award

Dramatic Improvements to the Doubly Labeled Water Technique by Measurement of 17O

Award identifier 8c2a78b57547337992569cf5976ef37227dc8aa8b444f88e50b9eafd98eb2574Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$572,564

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MARTINGALE RESEARCH CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
T9NGMH8MYAR3
Solicitation number
PA12-088
Topic code
NIGMS

Research abstract

DESCRIPTION (provided by applicant): Improving statistical methods to provide better inferences and new analytical capabilities for categorical regression models would be invaluable to the medical and health-related research communities. Presently, singleregression models are used extensively to identify patterns of disease-related symptoms, screen for disorders, analyze the results of clinical trials, and for the assessment and justification of public health policies. However, while single model estimation and inference is widely used in health-related studies, such approaches neglect model uncertainty, thus abrogating the opportunity to: i) detect additional statistical regularities (e.g., treatment effects, risk factors), ii) improve the precision of statistical inferences for estimation and prediction/classification (e.g., patient screening, diagnosis), iii) control for overfitting (e.g., model selection bias), and iv) include different yet highly correlated risk factors. This Phase I study investigatesthe feasibility of combining robust estimators and specification analysis methods within a multimodel framework to create a robust multimodel estimation and inference technology that addresses the limitations of the single model approach. Robust multimodeling is a specific type of Frequentist Model Averaging (FMA) methodology. First, an important feature of this approach is that it provides robust confidence intervals on predictions and effect sizes averaged across multiple models, which simultaneously incorporate sources of uncertainty that arise from the presence of many different (yet equally appropriate) models of the same data generating process as well as sources of uncertainty resulting from sampling error. A second feature of our robust multimodeling approach is that it has a robust Bayesian Model Averaging (BMA) interpretation. Specifically, theoretical arguments establish that all inferences are robust with respect to the presence of model misspecification. Third, previous work in the BMA and FMA literature has tended to focus upon using the most probable models constrained within a model space by applying Occam's Window to identify a group of best models, rather than all possible models in computationally tractable model spaces. In this Phase I study, alternative strategies for multimodel estimation and inference involving large model spaces will be empirically studied with extensive simulations using realistic models on clinical trial datasets (NIDA-CTN, NIMH-STAR*D). Finally, Phase I feasibilityresults will provide the preliminary research and design for the Phase II prototype software and support technology dissemination through collaborative health-related research projects to establish the essential foundation for Phase III product commercialization. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Improving statistical methods for clinical trials and observational studies that provide better inferences from categorical regression models would be invaluable to clinical science, epidemiology, and health services research. This Phase I study builds on prior work in statistical theory, software development, and applied research to develop a multimodel paradigm that makes robust inferences in the simultaneous presence of model uncertainty, possible model misspecification, and multicollinearity. This Phase I feasibility study will: i) demonstrate the applicability of the new technology on NIH-sponsored clinical trial datasets (NIDA-CTN, NIMH-STAR*D), ii) provide the preliminary research and design for Phase II prototype software, iii) support technology dissemination through collaborative health-related research projects, and iv) establish the initial foundation for Phase III product commercialization

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

32 SBIR/STTR records share this UEI (1987–2019). Reported award amounts total $10,833,491. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, National Aeronautics and Space Administration

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.